Iradimed (IRMD) director adds 905 shares through RSU vesting

Rhea-AI Filing Summary

Iradimed Corporation reported an insider equity transaction by director James B. Hawkins. On December 11, 2025, 905 shares of common stock were acquired following the conversion of restricted stock units, at an exercise price of $0. After this transaction, Hawkins directly beneficially owns 29,647 shares of Iradimed common stock.

The derivative position involved 905 restricted stock units that converted into an equal number of common shares on a one-for-one basis. These units were originally granted on December 11, 2024 under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning on December 11, 2025. Following the reported transaction, 906 restricted stock units remain beneficially owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAWKINS JAMES B

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		M		905	A	(1)	29,647	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	12/11/2025		M			905	(2)	(2)	Common Stock	905	$0	906	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

	/s/ James B. Hawkins	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Iradimed (IRMD) report in this filing?

The filing reports that director James B. Hawkins acquired 905 shares of Iradimed common stock on December 11, 2025 through the conversion of restricted stock units at an exercise price of $0.

How many Iradimed (IRMD) shares does James B. Hawkins own after this transaction?

After the reported transaction, James B. Hawkins beneficially owns 29,647 shares of Iradimed Corporation common stock in direct ownership.

What derivative securities were involved in the Iradimed (IRMD) insider transaction?

The transaction involved restricted stock units. A total of 905 restricted stock units were converted into 905 shares of common stock, and 906 restricted stock units remain beneficially owned following the transaction.

Under what plan and when were the restricted stock units for Iradimed (IRMD) granted?

The restricted stock units were granted on December 11, 2024 under Iradimed Corporation's 2023 Equity Incentive Plan, as disclosed in the explanation of responses.

How do the restricted stock units for Iradimed (IRMD) vest?

The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon each vesting, the reporting person receives one share of common stock for each vested unit.

What is the reporting person's relationship to Iradimed (IRMD)?

The reporting person, James B. Hawkins, is a director of Iradimed Corporation, as indicated in the relationship section of the report.

Is this Iradimed (IRMD) insider report filed by one or multiple reporting persons?

The form indicates it is filed by one reporting person, not by a group or multiple reporting persons.